Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU to extend COVID vaccine export controls to end of June - sources

Thu, 04th Mar 2021 11:46

(adds context)

By Francesco Guarascio and John Chalmers

BRUSSELS, March 4 (Reuters) - The European Union is planning
to extend its export authorisation scheme for COVID-19 vaccines
to the end of June, two EU sources told Reuters on Thursday, in
a move that could reignite tensions with countries who rely on
shots made in the EU.

The mechanism was set up at the end of January as a reaction
to vaccine makers' announcements of delays in the deliveries of
COVID-19 vaccines to the EU.

It is due to expire at the end of March, but the European
Commission wants to extend it through June, the two officials
said.

"The Commission will propose its extension into June. And
that was greeted by the member states with approval, not
necessarily enthusiasm, but there is a feeling that we still
need that mechanism," one senior EU diplomat said.

The second official added that at a meeting with EU
diplomats on Wednesday, many countries supported the measure,
including heavyweights Germany and France.

The EU Commission was not immediately available for a
comment.

Italian Prime Minister Mario Draghi has also called for
sanctions on companies that do not respect their contractual
obligations with the EU.

When the EU's export control mechanism was introduced in
late January it triggered an outcry from importing countries who
feared their vaccine supplies might have been hampered.

Under the scheme, companies must get an authorisation before
exporting COVID-19 shots, and may have export requests denied if
they do not respect their supply commitments with the EU.

However, the EU has authorised all requests for export since
the scheme's debut on Jan. 30 to Feb. 26, which amounted to 150
requests for millions of shots to 29 countries, including
Britain, the United Arab Emirates and Canada, an EU Commission
spokeswoman said.

She added, however, that at least one request was withdrawn
by an exporting company. She declined to elaborate.

Export requests mostly concern the Pfizer-BioNTech
vaccine which is manufactured in Belgium. AstraZeneca
and Moderna shots have also been exported from
the EU.

Since Jan. 30 more than 8 million vaccines were shipped from
the EU to Britain, a third EU source said.

Britain has so far prevented the export of AstraZeneca
vaccines to the EU, using a UK-first clause in its supply
contract with the Anglo-Swedish firm, EU officials have said.

The United States also has regulations that effectively ban
vaccine exports, the head of the European Commission Ursula von
der Leyen told a news conference last week.
(Reporting by Francesco Guarascio @fraguarascio and John
Chalmers; Editing by Toby Chopra)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.